Janssen submits esketamine nasal spray new drug application to U.S. FDA for treatment-resistant depression

4 September 2018 - Janssen today announced the submission of a new drug application to the U.S. FDA for esketamine ...

Read more →

FDA grants priority review to Merck’s supplemental biologics license application for Keytruda (pembrolizumab) for the treatment of Merkel cell carcinoma, a rare form of skin cancer

4 September 2018 - Application based on data from Phase 2 KEYNOTE-017 trial. ...

Read more →

Biosimilar medicines are the key to success

3 September 2018 - The lives of more than 10 million Americans — those with rheumatoid arthritis, psoriatic arthritis, ankylosing ...

Read more →

You’ll never guess which company is reinventing health benefits

31 August 2018 - Frustrated with insurers, some large companies — including a certain cable behemoth — are shedding long-held practices ...

Read more →

Cablivi (caplacizumab) approved in Europe for adults with acquired thrombotic thrombocytopenic purpura

3 September 2018 - In addition, U.S. FDA to conduct priority review of caplacizumab with a target action date of ...

Read more →

FDA grants Insys Therapeutics ‘fast track’ designation for epinephrine nasal spray as investigational treatment for anaphylaxis

30 August 2018 - Insys Therapeutics announced today that the U.S. FDA has granted fast track designation to the company’s epinephrine ...

Read more →

FDA issues a complete response letter for new drug application for dasatroline for the treatment of ADHD

31 August 2018 - Sunovion Pharmaceuticals today announced that the U.S. FDA issued a complete response letter for the new ...

Read more →

Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review

1 September 2018 - Although patient-reported outcomes, such as health-related quality of life, are important endpoints in randomised controlled trials, there ...

Read more →

Choice of control group in randomised trials of cancer medicine: are we testing trivialities?

31 August 2018 - Several trials in cancer medicine over the past 5 years share two common features: first, they were ...

Read more →

FDA approves Merck’s Delstrigo (doravirine with lamivudine and tenofovir disoproxil fumarate), a once daily fixed-dose combination tablet as a complete regimen and Pifeltro (doravirine), an NNRTI, both for the treatment of HIV-1 in appropriate patients

30 August 2018 - Approvals based on findings from the pivotal Phase 3 DRIVE-AHEAD and DRIVE-FORWARD trials evaluating the efficacy and ...

Read more →

FDA’s comprehensive effort to advance new innovations: initiatives to modernise for innovation

29 August 2018 - Our longstanding goal for medical care is to ensure that the right drug or device is delivered ...

Read more →

Bayer receives US approval for modern haemophilia A treatment Jivi with a step-wise prophylaxis dosing regimen

30 August 2018 - Jivi’s extended half-life allows for twice-weekly initial dosing / May be adjusted to every five days and ...

Read more →

U.S. Food and Drug Administration accepts Bristol-Myers Squibb’s application for Sprycel (dasatinib) in paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia

30 August 2018 - Application based on results from Phase 2 CA180-372 study. ...

Read more →

FDA accepts resubmission of new drug application for Duobrii (halobetasol propionate and tazarotene) lotion

29 August 2018 - Ortho Dermatologics today announced that the U.S. FDA has accepted the resubmitted new drug application for Duobrii ...

Read more →

Surprise! Trump might actually lower drug prices.

29 August 2018 - Surprise! The Trump administration is actually making progress to reduce drug prices, and not just by ...

Read more →